JP2008543854A5 - - Google Patents

Download PDF

Info

Publication number
JP2008543854A5
JP2008543854A5 JP2008517028A JP2008517028A JP2008543854A5 JP 2008543854 A5 JP2008543854 A5 JP 2008543854A5 JP 2008517028 A JP2008517028 A JP 2008517028A JP 2008517028 A JP2008517028 A JP 2008517028A JP 2008543854 A5 JP2008543854 A5 JP 2008543854A5
Authority
JP
Japan
Prior art keywords
group
compound
ester
salt
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008517028A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008543854A (ja
Filing date
Publication date
Priority claimed from US11/151,174 external-priority patent/US8338648B2/en
Application filed filed Critical
Publication of JP2008543854A publication Critical patent/JP2008543854A/ja
Publication of JP2008543854A5 publication Critical patent/JP2008543854A5/ja
Pending legal-status Critical Current

Links

JP2008517028A 2005-06-13 2006-06-13 炎症状態を治療するための組成物および方法 Pending JP2008543854A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/151,174 US8338648B2 (en) 2004-06-12 2005-06-13 Topical compositions and methods for epithelial-related conditions
PCT/US2006/023022 WO2006135894A1 (en) 2005-06-13 2006-06-13 Compositions and methods for treating inflammatory conditions

Publications (2)

Publication Number Publication Date
JP2008543854A JP2008543854A (ja) 2008-12-04
JP2008543854A5 true JP2008543854A5 (enExample) 2009-07-30

Family

ID=37532638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008517028A Pending JP2008543854A (ja) 2005-06-13 2006-06-13 炎症状態を治療するための組成物および方法

Country Status (5)

Country Link
US (4) US8338648B2 (enExample)
EP (1) EP1899480A4 (enExample)
JP (1) JP2008543854A (enExample)
CA (1) CA2611500A1 (enExample)
WO (1) WO2006135894A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338648B2 (en) 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
US20060269507A1 (en) * 2005-05-27 2006-11-30 Susan Fuller Topical ointment compostion and method for making the same
US20070092571A1 (en) * 2005-10-25 2007-04-26 Schur Henry B Non-irritating formulation and method for the intradermal delivery of substances
US20070166273A1 (en) * 2006-01-19 2007-07-19 Krivulka Joseph J Skin treatment educational kit
KR100941854B1 (ko) * 2006-09-01 2010-02-11 (주)아모레퍼시픽 오메가-3 지방산을 함유하는 피부 외용제 조성물
US20080138417A1 (en) * 2006-11-22 2008-06-12 Charles Grigsby Topical Composition And Method Of Forming
JP4300370B2 (ja) * 2007-03-13 2009-07-22 春三 小林 上皮改善剤
US20120141576A1 (en) * 2007-03-15 2012-06-07 Benjamin Johnson Treatment of Dermatologic Skin Disorders
US20080241290A1 (en) * 2007-03-30 2008-10-02 Wayne Jeffrey Perry Sinus relief composition and method of producing the same
US20130115320A1 (en) 2007-03-30 2013-05-09 Dynova Laboratories, Inc. Therapeutic agent for intranasal administration and method of making and using same
US20080242741A1 (en) * 2007-03-30 2008-10-02 Wayne Jeffrey Perry Intranasal drug delivery system
US20090053319A1 (en) * 2007-08-21 2009-02-26 Wayne Jeffrey Perry Sore Throat Relief Composition And Method of Producing Same
US20090069446A1 (en) * 2007-09-06 2009-03-12 Wayne Jeffrey Perry Dendritic salt therapeutic agent delivery system
US20090069433A1 (en) * 2007-09-10 2009-03-12 Wayne Jeffrey Perry Nasal rinse additive
US20090130232A1 (en) * 2007-11-20 2009-05-21 Mohammed Zahra Composition and method for treatment of oral inflammation an ulceration
BRPI0819976A2 (pt) * 2007-12-03 2019-02-12 Signum Biosciences, Inc. composto mimético de ácido para a inibição de isoprenil-s-cisteinil metiltransferase, composição compreedendo os mesmos, bem como uso dos ditos compostos.
US20110053901A1 (en) * 2008-02-14 2011-03-03 Signum Biosciences, Inc. Acetyl mimic compounds for the inhibition of isoprenyl-s-cysteinyl methyltransferase
CN101945886A (zh) * 2008-02-25 2011-01-12 西格纳姆生物科学公司 采用含有脂质修饰半胱氨酸的肽的局部组合物和方法
PT2362866E (pt) * 2008-11-11 2015-10-26 Signum Biosciences Inc Compostos de isoprenila e métodos dos mesmos
US8461204B2 (en) 2008-11-11 2013-06-11 Signum Biosciences, Inc. Cysteinyl compounds, compositions and methods of use
CN102655745B (zh) 2009-11-12 2016-01-06 西格纳姆生物科学公司 抗细菌剂用于治疗上皮相关病况的用途
WO2011109505A2 (en) * 2010-03-02 2011-09-09 Mankovitz Roy J Non-toxic and environmentally compatible photo-protective preparations
US8685309B2 (en) * 2010-04-26 2014-04-01 The Procter & Gamble Company Method for making a personal care product
EP2590640A1 (en) * 2010-07-08 2013-05-15 Ramot at Tel-Aviv University Ltd Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions
WO2012004799A1 (en) * 2010-07-08 2012-01-12 Ramot At Tel-Aviv University Ltd. Treatment of delayed cutaneous hypersensitivity conditions with s-farnesylthiosalicylic acid and analogs thereof
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
RU2649364C2 (ru) 2011-12-16 2018-04-02 Модерна Терапьютикс, Инк. Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
MX2015003074A (es) * 2012-09-14 2015-11-09 Arden Elizabeth Inc Formulaciones que comprenden idebenona, n-acetil-s-farnesil-l-cist eína y ergotioneína y usos de las mismas.
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
BR112015015788A2 (pt) * 2012-12-31 2017-07-11 Jrx Biotechnology Inc formulações farmacêuticas de nano-emulsão tópicas líquidas
EP3434774A1 (en) 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
US10639439B2 (en) 2013-01-30 2020-05-05 Midwest Pharmaceuticals, Llc Smokeless THC and administration method thereof
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
TWI629062B (zh) * 2013-03-13 2018-07-11 香港商安能泰製藥有限公司 含有局部麻醉劑之局部用抗病毒組合物及其製備方法
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
US9078853B2 (en) 2013-06-18 2015-07-14 Cmpd Licensing, Llc Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders
RU2557894C2 (ru) * 2013-10-18 2015-07-27 Общество с ограниченной ответственностью "Фарма Ген" (ООО "Фарма Ген") Косметическое средство для быстрого восстановления кожи
US20170224757A1 (en) 2014-07-22 2017-08-10 Signum Nutralogix, Inc. Natural extracts for modulating pp2a methylation, and providing antioxidant and anti inflammatory activity
US10172786B2 (en) * 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
BR112018005315A2 (pt) 2015-09-17 2018-10-09 Jrx Biotechnology Inc abordagens para aprimorar hidratação ou umidificação de pele
CA3021929A1 (en) 2016-05-12 2017-11-16 Unilever Plc Method for stabilizing retinoic acid precursors and a skin benefit composition with stabilized retinoic acid precursors
CN110114051B (zh) 2016-08-19 2022-04-08 联合利华知识产权控股有限公司 抗微生物组合物
CN109640930B (zh) 2016-08-19 2021-11-26 联合利华知识产权控股有限公司 抗微生物组合物
US11737975B2 (en) 2016-11-17 2023-08-29 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US10966946B2 (en) 2016-11-17 2021-04-06 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US11986448B2 (en) 2016-11-17 2024-05-21 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US10716758B2 (en) * 2018-04-09 2020-07-21 Southwest Research Institute Liposomal statin formulation
WO2019226548A1 (en) * 2018-05-22 2019-11-28 Weinberg Assa Methods for prevention and treatment of urogenital atrophy of menopause by contact vasodilators
MX2020013192A (es) 2018-06-04 2021-08-16 Arcutis Inc Metodo y formulacion para mejorar el tiempo de retraso de penetracion en la piel de roflumilast.
CN116963717A (zh) 2020-12-04 2023-10-27 阿尔库缇斯生物疗法股份有限公司 具有抗真菌性能的局部用罗氟司特制剂
AU2022429340A1 (en) 2021-12-28 2024-08-01 Arcutis Biotherapeutics, Inc. Topical roflumilast aerosol foams
CN120166935A (zh) 2022-09-15 2025-06-17 阿尔库缇斯生物疗法股份有限公司 罗氟司特和能够溶解大量该药物的溶剂的药物组合物
CN118217280B (zh) * 2024-01-30 2024-09-17 青岛农业大学 瑞香素在防治碳青霉烯耐药肠杆菌的药物组合物中的应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294852A (en) * 1973-11-01 1981-10-13 Johnson & Johnson Skin treating compositions
US4380549A (en) * 1975-07-23 1983-04-19 Scott Eugene J Van Topical treatment of dry skin
PH18373A (en) * 1982-02-02 1985-06-13 Unilever Nv Skin treatment composition
US4478853A (en) * 1982-05-17 1984-10-23 S. C. Johnson & Son, Inc. Skin conditioning composition
US4552872A (en) * 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
US5019569A (en) * 1986-11-03 1991-05-28 Ortho Pharmaceutical Corporation Reversal of glucocorticoid-induced skin atrophy
US5188826A (en) * 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US5284867A (en) * 1989-11-07 1994-02-08 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA-blocking pharmaceutical compositions
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5043268A (en) * 1990-05-04 1991-08-27 The Trustees Of Princeton University Substrates and inhibitors for prenyl cysteine methyltransferase enzymes
US6096740A (en) * 1990-11-06 2000-08-01 Ramot University Authority For Applied Research And Industrial Development Ltd. Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
TW198008B (enExample) * 1991-04-08 1993-01-11 Green Cross Corp
US5310545A (en) * 1991-04-11 1994-05-10 Drore Eisen Method of treatment using mouthwashes containing steroids and antifungal agents and compositions of matter
US5202456A (en) * 1991-04-15 1993-04-13 The President And Fellows Of Harvard College Compounds for inhibition of protein methylation
US5451700A (en) * 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
JP2636118B2 (ja) * 1991-09-10 1997-07-30 三省製薬株式会社 育毛剤
US5789541A (en) * 1992-07-14 1998-08-04 President And Fellows Of Harvard College Compounds for inhibition of proteolysis
US5455274A (en) * 1992-12-09 1995-10-03 Ciba-Geigy Corporation Hydroxyamidine derivatives
US5482710A (en) * 1993-07-30 1996-01-09 Chesebrough-Pond'usa Co., Division Of Conopco, Inc. Cosmetic composition for treatment of pimples and redness
US5567729A (en) * 1993-10-28 1996-10-22 David L. Bradfute Farnesyl compounds as farnesyl protein transferase inhibitors to treat ras induced tumor growth
IL107587A (en) * 1993-11-12 1998-08-16 Univ Ramot Farnesyl geranyl or geranyl-geranyl derivatives pharmaceutical compositions containing them and methods for their preparation
US5470882A (en) * 1994-06-02 1995-11-28 Smithkline Beecham Corp. Anti-inflammatory compounds
US5571687A (en) * 1994-06-07 1996-11-05 Duke University Modulators of multidrug resistance transporters
WO1995034303A1 (en) * 1994-06-13 1995-12-21 Arcturus Pharmaceutical Corporation Method for the treatment, prevention or minimization of hair loss
US5658881A (en) * 1994-10-14 1997-08-19 Twk, Inc. Method for topical inhibition of the metabolic activity of cytochrome P450
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US5618522A (en) * 1995-01-20 1997-04-08 The Procter & Gamble Company Emulsion compositions
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
US6015877A (en) * 1996-03-14 2000-01-18 President And Fellows Of Harvard College Compounds for inhibition of proteolysis
WO1998038509A1 (en) * 1997-02-26 1998-09-03 Thyreos Corporation Drug screen targeting lipoprotein-membrane anchorage
US6414037B1 (en) * 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
US6251882B1 (en) * 1998-06-29 2001-06-26 Parker Hughes Institute Alkyl ketones as potent anti-cancer agents
US6337065B1 (en) * 1998-12-01 2002-01-08 University Of Kentucky Research Foundation Method for enhancing protective cellular responses to genotoxic stress in skin
US6159485A (en) 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
ATE309205T1 (de) * 1999-01-13 2005-11-15 Warner Lambert Co Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren
US20020115696A1 (en) * 1999-06-18 2002-08-22 Yoel Kloog Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists
CA2377254C (en) * 1999-06-18 2009-08-18 Thyreos Corporation Non-malignant disease treatment with ras antagonists
CA2378892C (en) * 1999-07-22 2008-07-15 Aventis Pharmaceuticals, Inc. Preserved pharmaceutical formulations
US6372793B1 (en) * 1999-08-20 2002-04-16 Florida Agricultural & Mechanical University Method for treatment of a neurological disease characterized by impaired neuromodulator function
US20020010128A1 (en) * 2000-04-13 2002-01-24 Parks Thomas P. Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
JP3433380B2 (ja) * 2000-06-07 2003-08-04 株式会社スクウェア・エニックス 球技系ゲームのプログラムを記録したコンピュータ読み取り可能な記録媒体、球技系ゲーム処理装置およびその方法
WO2002030453A1 (en) * 2000-10-12 2002-04-18 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting angiogenesis using nadph oxidase inhibitors
FR2816943B1 (fr) * 2000-11-22 2004-02-13 Inst Nat Sante Rech Med Derives de la biotine, leurs procedes de fabrication et leurs utilisations en tant que vecteurs
WO2002060426A2 (en) * 2001-01-03 2002-08-08 President And Fellows Of Harvard College Compounds regulating cell proliferation and differentiation
FR2822238B1 (fr) * 2001-03-16 2003-08-29 Gemac Methode et trousse pour le suivi des maladies neurodegeneratives
US20020182237A1 (en) * 2001-03-22 2002-12-05 The Procter & Gamble Company Skin care compositions containing a sugar amine
US20030180719A1 (en) * 2001-04-13 2003-09-25 Thomas Herget Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis C virus infections
US7341717B2 (en) * 2001-04-13 2008-03-11 Gpc Biotech Ag Therapeutic targets for treatment of HCV infections, methods of treating HCV infections and compounds useful therefor
JP2005505540A (ja) * 2001-08-27 2005-02-24 メディテック リサーチ リミテッド 改善された治療プロトコール
US20030059450A1 (en) * 2001-09-24 2003-03-27 Maibach Howard I. Method and topical formulation for treating skin conditions associated with aging
US20030124205A1 (en) * 2001-12-28 2003-07-03 Avon Products, Inc. Topical cosmetic composition having a natural plant active ingredient and method of using same
US6881427B2 (en) * 2002-01-31 2005-04-19 Alticor Inc. Topical anti-inflammatory composition containing linseed and licorice extracts
AU2003220222A1 (en) 2002-03-13 2003-09-29 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
US20030228688A1 (en) * 2002-05-31 2003-12-11 Isis Pharmaceuticals Inc. Antisense modulation of isoprenylcysteine carboxyl methyltransferase expression
AU2003280867A1 (en) 2002-11-04 2004-06-07 Charite-Universitatsme Dizin Berlin Specific haplotypes of the mdr1 gene and their use in diagnosis and therapy
IL154306A0 (en) * 2003-02-05 2003-09-17 Rimonyx Pharmaceuticals Ltd Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof
US20070004803A1 (en) * 2003-03-26 2007-01-04 Purdue Research Foundation Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase
US8338648B2 (en) 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
AU2005254035B2 (en) * 2004-06-12 2011-03-24 Elizabeth Arden, Inc. Topical compositions and methods for epithelial-related conditions
US7846915B2 (en) * 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
JP2008523145A (ja) * 2004-12-13 2008-07-03 イーライ リリー アンド カンパニー リポキシゲナーゼ阻害剤としてのスピロ誘導体
US7964629B2 (en) 2005-03-18 2011-06-21 Duke Universtiy Inhibitors of isoprenylcysteine carboxyl methyltransferase
FR2886153B1 (fr) 2005-05-27 2009-04-10 Gemac Sa Composition destinee au traitement de la sclerose en plaques

Similar Documents

Publication Publication Date Title
JP2008543854A5 (enExample)
JP2021063088A5 (enExample)
JP2010532768A5 (enExample)
JP2006526590A5 (enExample)
JP2005523922A5 (enExample)
JP2013508279A5 (enExample)
JP2013534248A5 (enExample)
CN113993860A (zh) 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物
JP2011528713A5 (enExample)
JP2009502743A5 (enExample)
JP2010519260A5 (enExample)
JP2009535352A5 (enExample)
JP2013542247A5 (enExample)
JP2010522756A5 (enExample)
JP2014526503A5 (enExample)
JP2020507589A5 (enExample)
JP2009530398A5 (enExample)
PE20030347A1 (es) Composiciones farmaceuticas, kits y procedimientos que comprenden combinaciones de agonistas/antagonistas de estrogenos, estrogenos y progestinas
JP2010090149A5 (enExample)
JP2003503449A5 (enExample)
JP2008534453A5 (enExample)
JP2011518176A5 (enExample)
JP2012508256A5 (enExample)
JP2011046708A5 (enExample)
JP2011527678A5 (enExample)